Microbial Inflammasome Priming Prevention
Target: NLRP3, CASP1, IL1B, PYCARD
Composite Score: 0.653
Price: $0.65▲30.1%
Citation Quality: Pending
neurodegeneration
Status: proposed
🔥 Neuroinflammation 🟢 Parkinson's Disease 🟡 ALS / Motor Neuron Disease 🔮 Lysosomal / Autophagy 🔴 Alzheimer's Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
B
Composite: 0.653
Top 35% of 1402 hypotheses
T5 Contested
Contradicted by evidence, under dispute
A
0.80
Top 20%
A+
0.90
Top 8%
B+
0.70
Top 47%
A
0.80
Top 20%
A
0.80
Top 22%
A+
0.90
Top 15%
B
0.60
Top 36%
A
0.80
Top 22%
A
0.80
Top 18%
B+
0.70
Top 27%
Evidence
5 supporting
|
0 opposing
Citation quality: 100%
Debates
1 session
A
Avg quality: 0.89
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Vagal Afferent Microbial Signal Modulation
Score: 0.621 | Target: GLP1R, BDNF
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.533 | Target: CLDN1, OCLN, ZO1, MLCK
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.511 | Target: SNCA, HSPA1A, DNMT1
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.480 | Target: TLR4, SNCA
Microbiome-Derived Tryptophan Metabolite Neuroprotection
Score: 0.427 | Target: AHR, IL10, TGFB1
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.384 | Target: TH, AADC
Description
Pathogenic gut bacteria prime peripheral macrophages through NLRP3 inflammasome activation, creating a systemic pro-inflammatory state that enhances neuroinflammation and dopaminergic neuron vulnerability. Selective inflammasome inhibitors combined with microbiome restoration could break this inflammatory cycle.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Microbial PAMPs
LPS and Bacterial Components"] --> B["TLR4 and PRR
Pattern Recognition"]
B -->|"Signal 1"| C["NF-kappaB Nuclear
Translocation"]
C --> D["Pro-IL1B and Pro-IL18
Transcription"]
E["ATP and Danger Signals
Extracellular"] -->|"Signal 2"| F["P2X7 Receptor
Activation"]
F --> G["Potassium Efflux
and ROS Generation"]
G --> H["NLRP3 Protein
Conformational Change"]
D --> I["Cytoplasmic Pro-IL1B
Accumulation"]
H --> J["PYCARD ASC Adapter
Recruitment"]
J --> K["Pro-CASP1
Oligomerization"]
K --> L["Active Caspase-1
Formation"]
I --> L
L -->|"Proteolytic Cleavage"| M["Mature IL1B
Release"]
L --> N["Gasdermin D
Pore Formation"]
M --> O["Neuroinflammatory
Cascade Activation"]
N --> P["Pyroptotic Cell Death
and DAMP Release"]
P --> Q["Microglial Activation
and Proliferation"]
Q --> R["Synaptic Dysfunction
and Neurodegeneration"]
S["NLRP3 Inhibitors
MCC950 Treatment"] -->|"Therapeutic Block"| H
T["Caspase-1 Inhibitors
VX-765 Compounds"] --> L
U["IL1B Antagonists
Anakinra Therapy"] --> O
O --> R
classDef normal fill:#4fc3f7,stroke:#2196f3
classDef therapeutic fill:#81c784,stroke:#4caf50
classDef pathology fill:#ef5350,stroke:#f44336
classDef outcome fill:#ffd54f,stroke:#ff9800
classDef molecular fill:#ce93d8,stroke:#9c27b0
class A,B,E,F normal
class H,J,K,L,I,M,N molecular
class O,Q,P pathology
class R outcome
class S,T,U therapeutic
class C,D,G normal
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations
5 with PMID
5 medium
Validation: 100%
5 supporting / 0 opposing
✓
For
(5)
(0)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 2CLIN 0GENE 3EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 5
NLRP3 inflammasome in neuroinflammation and central nervous system diseases. MEDIUM
Microglial CMPK2 promotes neuroinflammation and brain injury after ischemic stroke. MEDIUM
NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer'… MEDIUM▼
NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING.
Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflam… MEDIUM▼
Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption.
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflam… MEDIUM▼
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition.
✗ Opposing Evidence 0
No evidence recorded
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 6 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Based on the provided literature on the gut-brain axis and Parkinson's disease, here are 7 novel therapeutic hypotheses:
1. Microbial Metabolite-Mediated α-Synuclein Disaggregation
Description: Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins. Therapeutic supplementation with SCFA-producing bacteria could prevent or reverse pathological protein aggregation in PD.
Target gene/protein: SNCA (α-synuclein), HSPA1A (HSP70), DNMT1
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and gaps in the evidence.
1. Microbial Metabolite-Mediated α-Synuclein Disaggregation
Critical Weaknesses:
- Mechanistic gap: No direct evidence that SCFAs can disaggregate α-synuclein in vivo. The leap from "SCFAs affect epigenetics" to "SCFAs disaggregate α-synuclein" lacks mechanistic validation.
- Blood-brain barrier assumptions: While some SCFAs cross the BBB, their concentrations and stability in brain tissue remain poorly characterized.
- Chaperone specificity: No evidence that SCFA-medi
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
REFINED DRUG DEVELOPMENT FEASIBILITY ASSESSMENT
Based on the additional data retrieved, I'm updating my feasibility rankings with concrete evidence from current research and clinical pipelines.
UPDATED HYPOTHESIS RANKINGS
1. NLRP3 Inflammasome Inhibition (Hypothesis #6)
Feasibility Score: 8/10 ⬆️ Upgraded based on new clinical dataKey Development Update:
- NT-0796 (PMID:40792655, 2025) showing anti-neuroinflammatory effects specifically in PD subjects
- KPT-8602 (PMID:35721113) demonstrating NF-κB/NLRP3 pathway inhibition in PD models
**Immediate Opportunities:
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↔
Stable
7d Momentum
▼ 1.4%
Volatility
Medium
0.0337
Events (7d)
6
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.560 | ▲ 1.4% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.553 | ▼ 5.4% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.584 | ▼ 0.3% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.586 | ▼ 2.0% | 2026-04-12 05:13 | |
| ⚖ | Recalibrated | $0.598 | ▼ 0.5% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.601 | ▲ 0.6% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.598 | ▼ 4.9% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.628 | ▼ 1.2% | 2026-04-06 06:48 | |
| ⚖ | Recalibrated | $0.636 | ▼ 10.1% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.708 | ▼ 0.5% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.711 | ▲ 0.7% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.707 | ▼ 0.4% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.710 | 2026-04-03 23:46 | ||
| ⚖ | Recalibrated | $0.709 | ▲ 7.2% | market_dynamics | 2026-04-03 01:06 |
| ⚖ | Recalibrated | $0.661 | ▼ 11.5% | market_dynamics | 2026-04-03 01:06 |
Clinical Trials (3) Relevance: 4%
0
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
Clinical trial NCT03808389
Unknown
Unknown
·
NCT03808389
Clinical trial NCT03671785
Unknown
Unknown
·
NCT03671785
Clinical trial NCT02269150
Unknown
Unknown
·
NCT02269150
📚 Cited Papers (87)
Bacterial Density and Biofilm Structure Determined by Optical Coherence Tomography.
Scientific reports (2019) · PMID:31278369
9 figures
Figure 1
2D cross-sectional OCT images of the four case biofilms evaluated. The scale bars indicate 100 µm.
pmc_api
Figure 2
Influence of the OCT focus point on the signal intensity distribution across a 2D cross-sectional image of a homogeneous agar layer. OCT images represent the cross-sectional view o...
pmc_api
Access to Kidney Transplantation after a Failed First Kidney Transplant and Associations with Patient and Allograft Survival: An Analysis of National Data to Inform Allocation Policy.
Clinical journal of the American Society of Nephrology : CJASN (2019) · PMID:31337621
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Rapid screening for and simultaneous semiquantitative analysis of thirty abused drugs in human urine samples using gas chromatography-mass spectrometry.
Journal of analytical toxicology (2006) · PMID:16959141
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Autophagy (2020) · PMID:30966861
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Electrical transportation mechanisms of molybdenum disulfide flakes-graphene quantum dots heterostructure embedded in polyvinylidene fluoride polymer.
Scientific reports (2019) · PMID:31043694
5 figures
Figure 1
( a ) TEM image of the MoS 2 flake decorated with GQDs. ( b ) TEM image of the GQDs on the MoS 2 . ( c ) HR-TEM image of the GQDs on the few-layer MoS 2 . ( d ) Fourier filtered H...
pmc_api
Figure 2
Schematic diagram of the sandwiched MIM device. ( a ) Reference device and ( b ) tristable switching device. ( c ) SEM cross-sectional structure characterization for the tristable ...
pmc_api
The Immuno-Glial Connectome in Alzheimer's Disease: Integrating Central and Peripheral Inflammatory Networks.
Cellular and molecular neurobiology (2026) · PMID:41569436
6 figures
Fig. 1
Dynamic microglial activation programs and signaling networks in Alzheimer’s disease (AD). Under physiological conditions, microglia exist in a state of homeostatic surveillance, w...
pmc_api
Fig. 2
Schematic representation of astrocytic activation and neuroinflammatory pathways in Alzheimer’s disease (AD). Exposure to amyloid-β (Aβ) or injury triggers reactive astrocytosis wi...
pmc_api
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.
Science translational medicine (2018) · PMID:30381407
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Rapid screening for and simultaneous semiquantitative analysis of thirty abused drugs in human urine samples using gas chromatography-mass spectrometry.
Journal of analytical toxicology (2006) · PMID:16959141
No extracted figures yet
Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
Clinical immunology (Orlando, Fla.) (2016) · PMID:27519954
No extracted figures yet
No extracted figures yet
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology.
Cell metabolism (2017) · PMID:28506519
No extracted figures yet
MyGeneFriends: A Social Network Linking Genes, Genetic Diseases, and Researchers.
Journal of medical Internet research (2017) · PMID:28623182
No extracted figures yet
📙 Related Wiki Pages (15)
NES Protein proteinNeurofilament Light Chain (NfL) in Blood - Biomark biomarkerNfL-Guided Neuroprotection Threshold ideaNeurofilament Light Chain (NfL) - Biomarker biomarkerCASP1 Gene genePYCARD Gene genePYCARD/ASC Protein proteinIL1B — Interleukin-1 Beta proteinIL1B Gene - Interleukin 1 Beta geneNLRP3 (NLR Family Pyrin Domain Containing 3) proteinCopper Dyshomeostasis in Neurodegeneration mechanismRaphe Serotonergic Neurons in Neurodegeneration cellSleep Optimization Therapy for Neurodegeneration therapeuticPerineuronal Nets in Neurodegeneration mechanismLipid Raft Dysfunction in Neurodegeneration mechanism
📓 Linked Notebooks (5)
📓 SciDEX Analysis: 2026 04 01 Gap 20260401 225155
Computational notebook for SDA-2026-04-01-gap-20260401-225155
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influ …
📓 Gut microbiome dysbiosis and Parkinsons disease -- Rich Analysis Notebook
Gene expression, pathway enrichment, statistical tests for: Gut microbiome dysbiosis and Parkinsons disease
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
⚔ Arena Performance
Variants (4)
📊 Resource Economics & ROI
Moderate Efficiency
Resource Efficiency Score
0.66
38.7th percentile (747 hypotheses)
Tokens Used
20,466
KG Edges Generated
19
Citations Produced
47
Cost Ratios
Cost per KG Edge
40.53 tokens
Lower is better (baseline: 2000)
Cost per Citation
660.19 tokens
Lower is better (baseline: 1000)
Cost per Score Point
28583.80 tokens
Tokens / composite_score
Score Impact
Efficiency Boost to Composite
+0.066
10% weight of efficiency score
Adjusted Composite
0.719
How Economics Pricing Works
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Efficiency Price Signals
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-17T09:10 | $0.629 | 0.532 |
Wiki Pages
NES ProteinproteinNeurofilament Light Chain (NfL) in Blood - BiomarkbiomarkerNfL-Guided Neuroprotection ThresholdideaNeurofilament Light Chain (NfL) - BiomarkerbiomarkerCASP1 GenegenePYCARD GenegenePYCARD/ASC ProteinproteinIL1B — Interleukin-1 BetaproteinIL1B Gene - Interleukin 1 BetageneNLRP3 (NLR Family Pyrin Domain Containing 3)proteinCopper Dyshomeostasis in NeurodegenerationmechanismRaphe Serotonergic Neurons in NeurodegenerationcellSleep Optimization Therapy for NeurodegenerationtherapeuticPerineuronal Nets in NeurodegenerationmechanismLipid Raft Dysfunction in Neurodegenerationmechanism
KG Entities (12)
GLP1_receptorNLRP3Parkinsons_diseaseSCFA_productionblood_brain_barriergut_microbiomeinflammasome_complexintestinal_barrierneuroinflammation_pathwayneuroprotectiontight_junction_proteinsvagal_signaling_pathway
Dependency Graph (5 upstream, 4 downstream)
Depends On
Senescent Cell Mitochondrial DNA Releasebuilds_on (1.0)SASP-Mediated Complement Cascade Amplificationbuilds_on (1.0)Multi-Modal Stress Response Harmonizationbuilds_on (1.0)Enteric Nervous System Prion-Like Propagation Blockadebuilds_on (1.0)Gut Barrier Permeability-α-Synuclein Axis Modulationbuilds_on (1.0)Depended On By
Vagal Afferent Microbial Signal Modulationbuilds_on (1.0)Microbiome-Derived Tryptophan Metabolite Neuroprotectionbuilds_on (0.6)Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegenerationrefines (0.5)Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates refines (0.5)Linked Experiments (10)
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk Cohortsclinical | tests | 0.40Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanismsclinical | tests | 0.40Microbiome-Gut Barrier Signatures in ALS — Experiment Designclinical | tests | 0.40Viral Infections and Alzheimer's Disease — causal mechanisms and therapeutic impclinical | tests | 0.40SCFA-Mediated Neuroinflammation in Alzheimer's Diseaseclinical | tests | 0.40Microbiome-Gut-Brain Axis in Alzheimer's Disease — mechanism and interventionclinical | tests | 0.40Viral and Post-Infectious Mechanisms in ALS — Experiment Designclinical | tests | 0.40Experiment: Autoimmune Hypothesis Testing in ADclinical | tests | 0.40Antiviral Therapy Trial for Parkinson's Diseaseclinical | tests | 0.40Regulated Necrosis Validation Study in Parkinson's Diseaseclinical | tests | 0.40
Related Hypotheses
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.888 | neurodegeneration
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration
Score: 0.822 | neurodegeneration
LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target
Score: 7.200 | neurodegeneration
Enteric Nervous System Dysfunction as Self-Reinforcing Pathological Loop
Score: 7.000 | neurodegeneration
Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propagation
Score: 6.000 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
18 months
🧪 Falsifiable Predictions (2)
2 total
0 confirmed
0 falsified
If hypothesis is true, intervention leverage liposomal encapsulation and targeted nanoparticle technologies to enhance compound bioavailability and cerebral penetrance
pending
conf: 0.90
Expected outcome: leverage liposomal encapsulation and targeted nanoparticle technologies to enhance compound bioavailability and cerebral penetrance
Falsified by: Intervention fails to leverage liposomal encapsulation and targeted nanoparticle technologies to enhance compound bioavailability and cerebral penetrance
If hypothesis is true, intervention be instrumental in comprehensively understanding the complex interactions underlying neuroinflammatory processes
pending
conf: 0.90
Expected outcome: be instrumental in comprehensively understanding the complex interactions underlying neuroinflammatory processes
Falsified by: Intervention fails to be instrumental in comprehensively understanding the complex interactions underlying neuroinflammatory processes
Knowledge Subgraph (7 edges)
associated with (2)
contributes to (1)
encodes component (1)
maintains (1)
mediates (1)
promotes (1)
Mechanism Pathway for NLRP3, CASP1, IL1B, PYCARD
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
NLRP3["NLRP3"] -->|encodes component| inflammasome_complex["inflammasome_complex"]
neuroinflammation_pathway["neuroinflammation_pathway"] -->|contributes to| Parkinsons_disease["Parkinsons_disease"]
GLP1_receptor["GLP1_receptor"] -->|mediates| vagal_signaling_pathway["vagal_signaling_pathway"]
vagal_signaling_pathway_1["vagal_signaling_pathway"] -->|promotes| neuroprotection["neuroprotection"]
tight_junction_proteins["tight_junction_proteins"] -->|maintains| intestinal_barrier["intestinal_barrier"]
gut_microbiome["gut_microbiome"] -->|associated with| SCFA_production["SCFA_production"]
SCFA_production_2["SCFA_production"] -->|associated with| blood_brain_barrier["blood_brain_barrier"]
style NLRP3 fill:#ce93d8,stroke:#333,color:#000
style inflammasome_complex fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation_pathway fill:#81c784,stroke:#333,color:#000
style Parkinsons_disease fill:#ef5350,stroke:#333,color:#000
style GLP1_receptor fill:#4fc3f7,stroke:#333,color:#000
style vagal_signaling_pathway fill:#81c784,stroke:#333,color:#000
style vagal_signaling_pathway_1 fill:#81c784,stroke:#333,color:#000
style neuroprotection fill:#ffd54f,stroke:#333,color:#000
style tight_junction_proteins fill:#4fc3f7,stroke:#333,color:#000
style intestinal_barrier fill:#4fc3f7,stroke:#333,color:#000
style gut_microbiome fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production_2 fill:#4fc3f7,stroke:#333,color:#000
style blood_brain_barrier fill:#4fc3f7,stroke:#333,color:#000
3D Protein Structure
🧬 NLRP3 — PDB 7PZC Click to expand 3D viewer
Source Analysis
What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!